Suven Life SciencesQ2 FY18

Suven Life Sciences Q2 FY18 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268.65Market Cap: ₹7.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4
  • Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond.
  • CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals.
  • Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline.
  • Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore.
  • Patient enrollment for Phase-2 clinical trials is progressing, with completion expected by late 2018 and data results by mid-2019, which may impact future growth.
  • Incremental growth also anticipated from preclinical compounds moving to Phase-1 clinical trials and planned Phase-2 trials for new molecules starting next year.

See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The management did not discuss raising capital via debt or equity during the call.
  • They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means.
  • The focus remains on progressing clinical trials and business growth without reference to external fundraising.
  • Any future financing needs were not addressed or indicated in this transcript.

See what Suven Life Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds.
  • The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore.
  • As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving.
  • The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year.
  • Total CAPEX for FY18 is expected to be around Rs. 90-100 crore.
  • For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs of Rs. 20-30 crore.
  • No other specific strategic investments were mentioned in this transcript.

Track Suven Life Sciences — get its next earnings analysis in your feed

How does Suven Life Sciences rank vs peers in Healthcare Services?

Pro feature
ThisSuven Life Sciences
Rev 4Mar 3

How does Suven Life Sciences rank in Healthcare Services?

Compare Suven Life Sciences against every Healthcare Services company (Q2 FY18) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →